2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 14:49, 21 November 2023
, 21 November 2023→Potential Benefits
| Line 125: | Line 125: | ||
| style="vertical-align:top; border:none;" | <br>[[File:NMN NAD+ Human.png|frameless|100px]] | | style="vertical-align:top; border:none;" | <br>[[File:NMN NAD+ Human.png|frameless|100px]] | ||
| style="vertical-align:top; border:none;" | | | style="vertical-align:top; border:none;" | | ||
* '''Safety''': basically safe under the existing intervention dose and time | * '''Safety''': basically safe under the existing intervention dose and time | ||
* '''Sleep quality''': no significant improvement^35,118 | * '''Sleep quality''': no significant improvement^35,118 | ||
* '''Physical activity''': prevented aging-related muscle dysfunctions and improving physical performance^118,141,145,146 | * '''Physical activity''': prevented aging-related muscle dysfunctions and improving physical performance^118,141,145,146 | ||